Latest News
BridgeBio reports exploratory PROPEL 3 data showing wider clinical trends for oral infigratinib
9 September 2026 - US biopharmaceutical company BridgeBio Pharma, Inc. (NASDAQ: BBIO), which develops medicines for genetic conditions, on Wednesday announced the release of new exploratory analyses from PROPEL 3, its global Phase 3 study of oral inf...
Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer
9 September 2026 - Biotechnology company Tyra Biosciences Inc (Nasdaq: TYRA) reported on Wednesday that its initial Phase 2 SURF302 results for oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder c...
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
9 September 2026 - Biopharmaceutical company Harbour BioMed (HKEX: 02142) reported on Wednesday that its partner company Solstice Oncology has launched with a USD225m Series A financing led by RA Capital Management, with participation from Canaan Par...
Kazia Therapeutics doses first patient in paediatric AT/RT study
9 September 2026 - Oncology-focused biotechnology company Kazia Therapeutics Limited (NASDAQ: KZIA) declared on Monday that the first patient has been dosed in the Arm A of PNOC035, a Phase 2 platform study evaluating paxalisib plus gemcitabine in pa...
Fusion Antibodies secures Canadian patent for OptiMAL
9 September 2026 - Fusion Antibodies plc (AIM: FAB), a specialist in pre-clinical antibody discovery, engineering and supply, announced on Wednesday that it has secured a Canadian patent for its OptiMAL antibody library technology. The Canadian Intel...